SCHEMBL23142089

SCHEMBL23142089

CC(C)(C)Cn1c(=O)ccc2cnc(Cl)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 3/20 0.46
▸ CCR9 P51686 3/20 0.45
▸ CDK4 P11802 5/20 0.40
▸ CCND1 P24385 5/20 0.40
▸ CCND2 P30279 5/20 0.40
▸ CCND3 P30281 5/20 0.40
▸ CTSS P25774 2/20 0.36
▸ CTSL P07711 1/20 0.36
▸ CDK2 P24941 2/20 0.35
▸ CDC7 O00311 1/20 0.35
▸ BRD4 O60885 1/20 0.34
▸ GRM2 Q14416 3/20 0.33
▸ PDE5A O76074 1/20 0.33
▸ CCNB2 O95067 1/20 0.33
▸ CCNE2 O96020 1/20 0.33
▸ CDK1 P06493 1/20 0.33
▸ FGFR1 P11362 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ CCNB1 P14635 1/20 0.33
▸ CCNA2 P20248 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17119621 0.85 BTK (0.58) BTKCCR9CDK4CCND1CCND2
SCHEMBL24680965 0.77 CCR9 (0.39) BTKCCR9CDK4CCND1CCND2
SCHEMBL31414483 0.75 NPC1 (0.38) BTKCCR9CDK4CCND1CCND2
SCHEMBL26604851 0.75 NPC1 (0.38) BTKCCR9CDK4CCND1CCND2
SCHEMBL29830402 0.74 HDAC1 (0.44) BTKCDK4CCND1CCND2CCND3
SCHEMBL23141974 0.73 CDK4 (0.43) CDK4CCND1CCND2CCND3CDK2
SCHEMBL5888197 0.72 PDE1A (0.47) CCR9CDK4CCND1CCND2CCND3
SCHEMBL17637279 0.72 HDAC1 (0.45) BTKCDK4CCND1CCND2CCND3
SCHEMBL30718883 0.71 CDK4 (0.49) CDK4CCND1CCND2CCND3CDK2
SCHEMBL28995586 0.69 JAK3 (0.47) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 — — US disclosed
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 — — US disclosed
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 — — US disclosed
CN-112469719-B Heterocondensed pyridone compounds and their use as IDH inhibitors 内尔维亚诺医疗科学公司 2024-01-23 — — CN disclosed
EP-3797107-B1 HETEROCONDENSED PYRIDONE COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2022-08-10 — — EP disclosed
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-07-08 — — US disclosed
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-07-08 — — US disclosed
EP-3797107-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2021-03-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors IDH1, IDH2, IDH3A BTK 869/4885CCR9 2444/4885CDK4 199/4885
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS IDH1, IDH2, IDH3A BTK 869/4885CCR9 2444/4885CDK4 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback